Bioblation: The procedure is performed under local anesthesia and a prostatic nerve block. Under real-time transrectal ultrasound (TRUS) visualization, four biopsy cores are taken transperineally from each suspected focal lesion, alongside systematic biopsies of the transitional zones. Immediately following the biopsy, 18G Chipa needles are inserted transperineally to pass 300-micron laser fibers to the target site. Using the Elesta system, 7W of laser energy is delivered via MRI-guided cognitive fusion to induce thermal coagulative necrosis of the tumor.
Study summary
This prospective study aims to validate the clinical outcomes of performing a concomitant trans-perineal prostate biopsy and laser ablation (termed "Bioblation") during a single session. The intervention is designed for symptomatic patients presenting with lower urinary tract symptoms (LUTS) who are highly suspected to have low to favorable intermediate-risk prostate cancer. By combining diagnosis and targeted treatment under local anesthesia, this approach seeks to facilitate early relief of severe symptoms and a rapid return to daily activities. Ultimately, the study evaluates whether this combined procedure decreases the patient's exposure to multiple, temporally separated interventions without compromising oncological safety or efficacy.
Eligibility
Sex
MALE
Min age
18 Months
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients with severe Lower Urinary Tract Symptoms (LUTS) meeting the following parameters:
1. IPSS score \> 20
2. Uroflowmetry flow rate \< 10 ml/sec
3. Post-void residual \> 150 cc
* Patients most probably having low to favorable intermediate-risk prostate cancer, defined as:
1. PSA level between 4 and 20 ng/ml
2. MP-MRI showing 3 or fewer focal lesions
3. MP-MRI focal lesions measuring \< 1.5 cm
* International or visiting patients requiring early return to their home country due to professional or personal commitments, provided they can undergo short-term management and follow-up coordination
Exclusion Criteria:
* Patient PSA level \> 20 ng/ml
* More than 3 focal lesions on MP-MRI
* Metastatic prostate cancer
* History of lower urinary tract surgery (e.g., TURP, Laser, urinary diversions, artificial urinary sphincter)
* History of pelvic radiation therapy or radical pelvic surgery
Primary outcome measure(s)
Change in International Prostate Symptom Score (IPSS) — Baseline, 1, 3, 6, 9, and 12 months post-procedure The IPSS is a validated questionnaire used to assess the severity of lower urinary tract symptoms (LUTS). The total score ranges from 0 to 35, where 0-7 indicates mildly symptomatic, 8-19 moderately symptomatic, and 20-35 severely symptomatic. A decrease in the score indicates an improvement in symptoms.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.